Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06254261 | A Study of RAY1225 in Participants With Obesity | PHASE2 | RECRUITING | 270 | — | — | Feb 21, 2024 | Dec 20, 2025 | Mar 19, 2025 | 1 | China |
Percent Change from Baseline in Body Weight
| Arm | Type | Description |
|---|---|---|
| RAY1225 (cohort 1) | EXPERIMENTAL | Participants received dose1 or dose2 RAY1225 administered subcutaneously (SC) once two week for 24 weeks. |
| Placebo (cohort 1) | PLACEBO_COMPARATOR | Participants received Placebo administered SC once two weeks for 24 weeks. |
| RAY1225 (cohort 2) | EXPERIMENTAL | Escalating doses of RAY1225 administered subcutaneously (SC) once two week |
| Placebo (cohort 2) | PLACEBO_COMPARATOR | Participants received Placebo administered SC once two week |
| Name | Type | Description |
|---|---|---|
| RAY1225 | DRUG | Administered SC |
| Placebo | DRUG | Placebo |
Inclusion Criteria: 1. Have a body mass index (BMI) of ≥28 kilogram per square meter (kg/m²) or ≥24 kg/m² and previously diagnosed with at least one of the following weight related comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, fatty liver disease,or HbA1c ≥5.7% and \< 6.5%; 2....